NCT07207486 · RECRUITING
In-depth Analysis of Cholesterol Metabolism and Related Biomarkers in the Pathogenesis and Progression of the Disease in Neurodegenerative Dementias
This study is examining how cholesterol metabolism — specifically breakdown products called oxysterols and a protein called PCSK9 — may contribute to Alzheimer's and other neurodegenerative dementias. Researchers will measure these markers in brain tissue, spinal fluid, and blood to see if cholesterol disruption is a shared feature across different dementia types. This is an observational study, not a drug trial — no treatment is being tested.
You may qualify if
- Age 40-85
- Diagnosis based on the current diagnostic criteria for AD (McKhann et al., 2011), FTD (Gorno-Tempini et al., 2011; Rascovsky et al., 2011), PSP and CBD (Amstrong et al., 2013; Höglinger et al., 2017)
- Mini Mental State Examination MMSE > 10.
You're excluded if
- Other neurological or psychiatric disorders Severe chronic metabolic diseases
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2026-02-11